|
|
|
| Analysis of the effect and mechanism of action of Astragalus Injection combined with Irbesartan in the treatment of hypertensive nephropathy |
| GUO Jia-yin1 PEI Ke2 ZHU Jing-jing3 XIE Qi-lian4 GUO Zhi-ling1 |
1.Department of Nephrology,Clinical Medical College of Henan University of Science and Technology the First Affiliated Hospital of Henan University of Science and Technology,Luoyang471003,China;
2.Drug Administration Section, Clinical Medical College of Henan University of Science and Technology the First Affiliated Hospital of Henan University of Science and Technology,Luoyang471003,China;
3.Department of Gastroenterology,Clinical Medical College of Henan University of Science and Technology the First Affiliated Hospital of Henan University of Science and Technology,Luoyang471003,China;
4.Department of Ophthalmology,Clinical Medical College of Henan University of Science and Technology the First Affiliated Hospital of Henan University of Science and Technology,Luoyang471003,China |
|
|
|
|
Abstract Objective To explore the clinical effect and its mechanism of Astragalus Injection combined with Irbesartan in the treatment of hypertensive nephropathy.Methods 94 cases of hypertensive nephropathy and who treated in our hospital from August 2014 to November 2015 were selected,and were divided into the combination group and the control group according to the different treatment methods,47 cases in each group.The control group was treated with Irbesartan alone,while the combination group was treated with Astragalus Injection combined with Irbesartan.Then,after treatment for one month,the changes of blood pressure,renal function,urinary protein of the two groups were compared. Results Diastolic blood pressure and systolic blood pressure after treatment in the two groups was lower than that before treatment,diastolic blood pressure and systolic blood pressure after treatment in the combination group was lower than that in the control group after treatment,with significant difference(P＜0.01).The level of serum cystatin C,SCr,BUN, NAG,α1-MG,24 h urinary protein quantitation after treatment in the two groups was lower than that before treatment, with significant difference(P＜0.05).The level of serum cystatin C,SCr,BUN,NAG,α1-MG,24 h urinary protein quantitation after treatment in the combination group was lower than that in the control group after treatment,with significant difference(P＜0.01).Conclusion The clinical effects of Astragalus Injection combined with Irbesartan in the treatment of hypertensive nephropathy is significant,which the renal function of the patients are restored,and the safety is high.
|
|
|
|
|
|
| [1] |
张慧，周易，李火平，等.黄芪联合厄贝沙坦治疗高血压肾病的疗效及机制研究[J].现代中西医结合杂志，2015，24（24）：158-160.
|
| [2] |
李志玲，徐新伟，柴萍，等.缬沙坦联合叶酸治疗老年高血压肾病的疗效研究[J].中国生化药物杂志，2014，23（24）：123-125.
|
| [3] |
葛灵利.黄芪用于辅治高血压肾病的临床观察[J].内蒙古中医药，2016，35（10）：46-47.
|
| [4] |
李霞，尹学亮.黄芪颗粒联合厄贝沙坦治疗高血压早期肾损害的疗效观察[J].国际医药卫生导报，2012，18（21）：3149-3152.
|
| [5] |
张新明，卢玲玲，涂斐佩，等.高血压肾病早期血尿NGAL水平的变化及临床意义[J].中国免疫学杂志，2014，10（12）：1672-1675.
|
| [6] |
马全中，郭志勇.高血压肾病的研究现状[J].中国医药导报，2012，9（33）：32-33.
|
| [7] |
李嘉雯.高血压肾病尿微量白蛋白NAG检测的临床意义研究[J].河北医学，2015，21（10）：1669-1671.
|
| [8] |
吴鹏，陈进，刘征兰，等.高血压肾病患者尿电导率与渗透压的相关性分析[J].海南医学，2016，27（33）：413-414.
|
| [9] |
高红勤，沈逸辛，唐安，等.健脾补肾方对高血压肾病的干预作用研究[J].现代中西医结合杂志，2015，12（27）：685-687.
|
| [10] |
陈明.高血压肾病检测视黄醇结合蛋白浓度水平的临床意义[J].中国实验诊断学，2014，7（11）：1877-1879.
|
| [11] |
杨碧梅.护理干预对高血压肾病患者健康状况的影响研究[J].当代护士，2016，9（11）：33-35.
|
| [12] |
师锁江，陈玉敏，程晓丽，等.氨氯地平联合厄贝沙坦在高血压肾病中的应用研究[J].疑难病杂志，2012，11（29）：663-664.
|
| [13] |
蒋琰，刘如石，李原，等.血清胱抑素C、同型半胱氨酸联合检测对诊断高血压早期肾病的意义[J].重庆医学，2015，27（29）：1193-1196.
|
| [14] |
熊义风.厄贝沙坦联合氨氯地平治疗高血压肾病的疗效观察[J].现代诊断与治疗，2014，25（10）：2233-2234.
|
| [15] |
姬静，朱沛宁，张璐萌，等.氨氯地平联合厄贝沙坦治疗高血压肾病的临床研究[J].中国处方药，2016，14（6）：73-74.
|
|
|
|
